Dysregulation of the homeobox transcription factor gene HOXB13: Role in prostate cancer

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2014, Pages 193-201

  Decker, Brennan ^a,b   Ostrander, Eelaine A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HOXB13; Prostate cancer risk

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HOXB13 PROTEIN; PROTEIN VARIANT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLELE; BIOLOGICAL FUNCTIONS; CANCER RISK; CHROMOSOME 17Q; EARLY DIAGNOSIS; EMBRYO DEVELOPMENT; FAMILIAL CANCER; FAMILY HISTORY; FOLLOW UP; GENE; GENE CONTROL; GENE LOCUS; GENETIC CONSERVATION; GENETIC LINKAGE; GENETIC TRANSCRIPTION; HERITABILITY; HOMEOBOX; HOMEOBOX TRANSCRIPTION FACTOR GENE; HUMAN; LINKAGE ANALYSIS; NONHUMAN; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEGREGATION ANALYSIS; TISSUE DIFFERENTIATION; TUMOR CELL LINE;

EID: 84905669015     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S38117     Document Type: Review

References (77)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11-30.
2. Grönberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol. 1994; 152(5 Pt 1): 1484-1487; discussion 1487-1489.
3. Lichtenstein P, Holm NV, Verkasalo PK, etal. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2): 78-85.
4. Verkasalo PK, Kaprio J, Koskenvuo M, Pukkala E. Genetic predisposition, environment and cancer incidence: a nationwide twin study in Finland, 1976-1995. Int J Cancer. 1999; 83(6): 743-749.
5. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992; 89(8): 3367-3371.
6. Conlon EM, Goode EL, Gibbs M, etal. Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer. 2003; 105(5): 630-635.
7. Gong G, Oakley-Girvan I, Wu AH, etal. Segregation analysis of prostate cancer in 1, 719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control. 2002; 13(5): 471-482.
8. Grönberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol. 1997; 146(7): 552-557.
9. MacInnis RJ, Antoniou AC, Eeles RA, etal. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol. 2010; 34(1): 42-50.
10. Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, etal. Segregation analysis of 1, 546 prostate cancer families in Finland shows recessive inheritance. Hum Genet. 2007; 121(2): 257-267.
11. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev. 2001; 10(7): 733-741.
12. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ; International Consortium for Prostate Cancer Genetics. Where are the prostate cancer genes?-A summary of eight genome wide searches. Prostate. 2003; 57(4): 261-269.
13. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008; 359(20): 2143-2153.
14. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci. 2007; 12: 4101-4110.
15. Nupponen NN, Carpten JD. Prostate cancer susceptibility genes: many studies, many results, no answers. Cancer Metastasis Rev. 2001; 20(3-4): 155-164.
16. Ostrander EA, Markianos K, Stanford JL. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet. 2004; 5: 151-175.
17. Pomerantz MM, Freedman ML. Genetics of prostate cancer risk. Mt Sinai J Med. 2010; 77(6): 643-654.
18. Verhage BA, Kiemeney LA. Inherited predisposition to prostate cancer. Eur J Epidemiol. 2003; 18(11): 1027-1036.
19. Eeles RA, Kote-Jarai Z, Al Olama AA, etal; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009; 41(10): 1116-1121.
20. Eeles RA, Kote-Jarai Z, Giles GG, etal; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008; 40(3): 316-321.
21. Eeles RA, Olama AA, Benlloch S, etal; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013; 45(4): 385-391, 391e1.
22. Kote-Jarai Z, Easton DF, Stanford JL, etal; PRACTICAL Consortium. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008; 17(8): 2052-2061.
23. Kote-Jarai Z, Olama AA, Giles GG, etal. Seven prostate cancer loci identified by a multi-stage genome-wide association study. Nat Genet. 2011; 43(8): 785-791.
24. Kote-Jarai Z, Saunders EJ, Leongamornlert DA, etal; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet. 2013; 22(12): 2520-2528.
25. Lu L, Cancel-Tassin G, Valeri A, etal; International Consortium for Prostate Cancer Genetics. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate. 2012; 72(4): 410-426.
26. Jin G, Lu L, Cooney KA, etal; International Consortium for Prostate Cancer Genetics. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2012; 131(7): 1095-1103.
27. Teerlink CC, Thibodeau SN, McDonnell SK, etal; International Consortium for Prostate Cancer Genetics. Association analysis of 9, 560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet. 2014; 133(3): 347-356.
28. Lange EM, Ho LA, Beebe-Dimmer JL, etal. Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Hum Genet. 2006; 119(4): 400-407.
29. Schaid DJ, McDonnell SK, Zarfas KE, etal; Investigators of the International Consortium for Prostate Cancer Genetics. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet. 2006; 120(4): 471-485.
30. Slager SL, Schaid DJ, Cunningham JM, etal. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet. 2003; 72(3): 759-762.
31. Slager SL, Zarfas KE, Brown WM, etal. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate. 2006; 66(2): 173-179.
32. Stanford JL, McDonnell SK, Friedrichsen DM, etal. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate. 2006; 66(3): 317-325.
33. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet. 2001; 68(5): 1197-1206.
34. Schaid DJ, Stanford JL, McDonnell SK, etal. Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet. 2007; 121(6): 729-735.
35. Witte JS, Goddard KA, Conti DV, etal. Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet. 2000; 67(1): 92-99.
36. Ewing CM, Ray AM, Lange EM, etal. Germline mutations in HOXB13 and prostate-cancer risk. N Eng J Med. 2012; 366(2): 141-149.
37. Lange EM, Gillanders EM, Davis CC, etal. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate. 2003; 57(4): 326-334.
38. Penney KL, Salinas CA, Pomerantz M, etal. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009; 15(9): 3223-3230.
39. Gillanders EM, Xu J, Chang BL, etal. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst. 2004; 96(16): 1240-1247.
40. Xu J, Dimitrov L, Chang BL, etal; ACTANE Consortium. A combined genomewide linkage scan of 1, 233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet. 2005; 77(2): 219-229.
41. Lange EM, Robbins CM, Gillanders EM, etal. Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. Hum Genet. 2007; 121(1): 49-55.
42. Lange EM, Chen H, Brierley K, etal. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res. 1999; 5(12): 4013-4020.
43. Stott-Miller M, Karyadi DM, Smith T, etal. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate. 2013; 73(6): 634-641.
44. Witte JS, Mefford J, Plummer SJ, etal. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev. 2013; 22(4): 675-680.
45. Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(8): 1348-1353.
46. Xu J, Lange EM, Lu L, etal; International Consortium for Prostate Cancer Genetics. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013; 132(1): 5-14.
47. MacInnis RJ, Severi G, Baglietto L, etal. Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PLoS One. 2013; 8(2): e54727.
48. Karlsson R, Aly M, Clements M, etal. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2014; 65(1): 169-176.
49. Schroeck FR, Zuhlke KA, Siddiqui J, Siddiqui R, Cooney KA, Wei JT. Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy. J Urol. 2013; 189(3): 849-853.
50. Chen Z, Greenwood C, Isaacs WB, etal. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis. 2013; 34(6): 1260-1264.
51. Lin X, Qu L, Chen Z, etal. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013; 73(2): 169-175.
52. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell. 1992; 68(2): 283-302.
53. Garcia-Fernàndez J. The genesis and evolution of homeobox gene clusters. Nat Rev Genet. 2005; 6(12): 881-892.
54. Zeltser L, Desplan C, Heintz N. Hoxb-13: A new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development. 1966; 122(8): 2475-2484.
55. Sreenath T, Orosz A, Fujita K, Bieberich CJ. Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate. 1999; 41(3): 203-207.
56. Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003; 130(10): 2061-2069.
57. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004; 64(24): 9185-9192.
58. Norris JD, Chang CY, Wittmann BM, etal. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell. 2009; 36(3): 405-416.
59. Kim SD, Park RY, Kim YR, etal. HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression. Anat Cell Biol. 2010; 43(4): 284-293.
60. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res. 2004; 64(9): 3046-3051.
61. Hamid SM, Cicek S, Karamil S, etal. HOXB13 contributes to G1/S and G2/M checkpoint controls in prostate. Mol Cell Endocrinol. 2014; 383(1-2): 38-47.
62. McMullin RP, Dobi A, Mutton LN, etal. A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland. Proc Natl Acad Sci U S A. 2010; 107(1): 98-103.
63. Huang H, Cai B. G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis. Tumour Biol. 2014; 35(2): 1177-1182.
64. Ren B, Yu G, Tseng GC, etal. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene. 2006; 25(7): 1090-1098.
65. Liu Z, Ren G, Shangguan C, etal. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene. PLoS One. 2012; 7(7): e40943.
66. Kim YR, Kim IJ, Kang TW, etal. HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis. Oncogene. Epub October 7, 2013.
67. Edwards S, Campbell C, Flohr P, etal. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer. 2005; 92(2): 376-381.
68. Jeong TO, Oh KJ, Xuan Nguyen NT, etal. Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer. Mol Med Rep. 2012; 5(4): 901-904.
69. Jung C, Kim RS, Zhang H, etal. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer. 2005; 92(12): 2233-2239.
70. Okuda H, Toyota M, Ishida W, etal. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene. 2006; 25(12): 1733-1742.
71. Yamashita T, Tazawa S, Yawei Z, etal. Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int J Oncol. 2006; 28(4): 931-938.
72. Miao J, Wang Z, Provencher H, etal. HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci U S A. 2007; 104(43): 17093-17098.
73. López R, Garrido E, Piña P, etal. HOXB homeobox gene expression in cervical carcinoma. Int J Gynecol Cancer. 2006; 16(1): 329-335.
74. Ma XJ, Wang Z, Ryan PD, etal. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004; 5(6): 607-616.
75. Jerevall PL, Brommesson S, Strand C, etal. Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat. 2008; 107(2): 225-234.
76. Shah N, Jin K, Cruz LA, etal. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Cancer Res. 2013; 73(17): 5449-5458.
77. Williams TM, Williams ME, Innis JW. Range of HOX/TALE superclass associations and protein domain requirements for HOXA13: MEIS interaction. Dev Biol. 2005; 277(2): 457-471.